参考文献:
[1] Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use ofantiplatelet drugs in patients having cardiac and noncardiac operations [J]. Ann Thorac Surg,2012 ,94(5):1761-1781. doi: 10.1016/j.athoracsur.2012.07.086.
[2] Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery:a scientific statement from the American Heart Association[J]. Circulation, 2015,131(10):927-964. doi: 10.1161/CIR.0000000000000182.
[3] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration ofDual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. [J]. J Am Coll Cardiol, 2016,68(10):1082-1115. doi: 10.1016/j.jacc.2016.03.513.
[4] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009,361(11):1045–1057. doi: 10.1056/NEJMoa0904327.
[5] Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med, 2015, 372(19):1791-1800. doi: 10.1056/NEJMoa1500857.
[6] Washam JB, Herzog CA, Beitelshees AL, et al. Pharmacotherapy in chronic kidney disease patients presenting with acutecoronary syndrome: a scientific statement from the American Heart Association. [J]. Circulation, 2015, 131(12):1123-1149. doi: 10.1161/CIR.0000000000000183.
[7] Sørensen R, Abildstrøm SZ, Hansen PR, et al. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction[J]. J Am Coll Cardiol, 2011,57(10):1202–1209. doi: 10.1016/j.jacc.2010.09.069.
[8] Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized,controlled trial[J]. J Am Coll Cardiol, 2010,56(20):1639–1643. doi: 10.1016/j.jacc.2010.03.104.
[9] 冠状动脉旁路移植术围术期抗血小板治疗共识专家组. 冠状动脉旁路移植术围术期抗血小板治疗专家共识[J]. 中华胸心血管外科杂志,2016,32(1): 1-8.doi:10.3760/cma.j.issn.1001-4497.2016.01.001.
Joint task force for the perioperative antiplatelet therapy of coronary artery bypass grafing of the Chinese Society for Thoracic and Cardiovascular Surgery. Chinese expert consensus statement on the treatment of the perioperative antiplatelet therapy of coronary artery bypass grafing [J]. Chin J Thorac Cardiovasc Surg, 2016, 32(1):1-8. doi:10.3760/cma.j.issn.1001-4497.2016.01.001.
[10] 中华医学会心血管病学分会介入心脏病学组, 中国医师协会心血管内科医师分会血栓防治专业委员会, 中华心血管病杂志编辑委员会中国经皮冠状动脉介入治疗指南(2016) [J]. 中华心血管病杂志, 2016,44(5):382-400. doi: 10.3760/cma.j.issn.0253-3758.2016.05.006.
2016 Chinese guideline of percutaneous coronary intervention treatment[J]. Chin J Cardiol, 2016, 44(5), 382-400. doi: 10.3760/cma.j.issn.0253-3758.2016.05.006.
[11] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). [J]. Eur Heart J, 2016, pii: ehw272. doi:10.1093/eurheartj/ehw272.
[12] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronaryartery bypass grafts[J]. N Engl J Med,1997,336(3):153–162.
[13]Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of bloodcholesterol to reduce atherosclerotic cardiovascular risk inadults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol, 2014,63(25 Pt B):2889-2934. doi: 10.1016/j.jacc.2013.11.002.
[14] Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-StatinTherapies for LDL-Cholesterol Lowering in the Management ofAtherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents [J]. J Am Coll Cardiol,2016, 68(1):92-125.doi:10.1016/j.jacc.2016.03.519.
[15] Weber MA, Schiffrin EL, White WB,et al.
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. [J]. J Hypertens, 2014,32(1):3-15. doi: 10.1097/HJH.0000000000000065.
[16] James PA, Oparil S, Carter BL,et al.2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee ( JNC 8) [J].JAMA,2014,311(5):507-520. doi: 10.1001/jama.2013.284427.
[17] Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery[J]. Circulation, 2008,117(1):24–31.
[18] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acuteand chronic heart failure: The Task Force for the diagnosis andtreatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. [J].Eur J Heart Fail, 2016,18(8):891-975. doi:10.1002/ejhf.592.
[19] 中华医学会心血管病学分会.2014 中国心力衰竭诊断与治疗指南[J].中华心血管病杂志, 2014,42(2): 98-122.doi:10.3760/cma.j.issn.0253-3758.2014.02.004
Chinese Society of Cardiology. 2014 Chinese guideline for the diagnosis and treatment of heart failure[J]. Chin J Cardiol. 2014,42(2): 98-122. doi:10.3760/cma.j.issn.0253-3758.2014.02.004.
[20] WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. [J]. Circulation, 2013, 128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776.
[21] Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. [J]. J Am Coll Cardiol,2016, pii: S0735-1097(16)33024-8. doi: 10.1016/j.jacc.2016.05.011.
[22] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014,371(11):993-1004. doi: 10.1056/NEJMoa1409077.
[23] Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010;376(9744):875-885. doi: 10.1016/S0140-6736(10)61198-1.
[24] Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into theACCF/AHA/HRS 2008 guidelines for device-based therapy ofcardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Forceon Practice Guidelines and the Heart Rhythm Society. [J]. Circulation, 2013,127(3):e283–
e352. doi: 10.1161/CIR.0b013e318276ce9b.
[25] American Diabetes Association. Diabetes care in the hospital. Diabetes Care,2016,39(Suppl 1):S99-S104. doi: 10.2337/dc16-S016.
[26] 中华医学会内分泌学分会.中国成人住院患者高血糖管理目标专家共识[J].中华内分泌代谢杂志, 2013,29(3):189-195. doi:10.3760/cma.j.issn.1000-6699.2013.03.002.
Chinese Society of Endocrinology. Chinese expert consensus statement on the management of hyperglycemia for inpatients[J]. Chin J End Met, 2013,29(3):189-195. doi:10.3760/cma.j.issn.1000-6699.2013.03.002.
[27] 中华医学会糖尿病分会.中国2型糖尿病防治指南[2013年版] [J].中国糖尿病杂志, 2014,22(8):2-42. doi:10.3760/cma.j.issn.1674-5809.2014.07.004
Chinese Diabetes Society. 2013 Chinese guideline for the prevention and treatment of type 2 diabetes[J]. Chin J Diabetes, 2014,22(8):2-42. doi:10.3760/cma.j.issn.1674-5809.2014.07.004.
[28] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志, 2013, 29(11):913-920. doi: 10.3760/cma.j.issn.1000-6699.2013.11.001.
Chinese Society of Endocrinology. Chinese expert consensus statement on the treatment of Hyperuricemia and gout[J]. Chin J End Met, 2013,29(11):913-920. doi: 10.3760/cma.j.issn.1000-6699.2013.11.001.
[29] 抗血小板药物消化道损伤的预防和治疗中国专家共识组.抗血小板药物消化道损伤的预防和治疗中国专家共识(2012年更新版) [J].中华内科杂志,2013, 53(3):264-270. doi: 10.3760/cma.j.issn.0578-1426.2013.03.027.
Joint task force for the prevention and treatment of gastrointestinal damage induced by anti-platelet agents of the Chinese Medical Association. 2012 Chinese expert consensus statement on the prevention and treatment of gastrointestinal damage induced by anti-platelet agents[J]. Chin J Intern Med,2013, 53(3):264-270. doi:10.3760/cma.j.issn.0578-1426.2013.03.027.
[30] 抗栓治疗消化道损伤防治专家组.抗栓治疗消化道损伤防治中国专家建议(2016·北京) [J]. 中华内科杂志,2016,55(7):564-566. doi: 10.3760/cma.j.issn.0578-1426.2016.07.020.
Joint task force for the prevention and treatment of gastrointestinal damage induced by antithrombotic therapy of the Chinese Medical Association. 2016 Chinese expert advice on the prevention and treatment of gastrointestinal damage induced by antithrombotic therapy[J]. Chin J Intern Med,2016,55(7):564-566. doi: 10.3760/cma.j.issn.0578-1426.2016.07.020.
[31] 中华医学会心血管病学分会,中国康复医学会心血管病专业委员会.冠心病康复与二级预防中国专家共识[J].中华心血管病杂志,2013,41(4):267-275. doi: 10.3760/cma.j.issn.0253-3758.2013.04.003.
Chinese Society of Cardiology. Cardiovascular Rehabilitation Branch-Chinese Association of Rehabilitation Medcicine. Chinese expert consensus statement on rehabilitation and secondary prevention of coronary heart disease[J]. Chin J Cardiol,2013,41(4):267-275. doi: 10.3760/cma.j.issn.0253-3758.2013.04.003.